A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Interventions: BIOLOGICAL: PDR001|DRUG: LCL161|DRUG: Everolimus|DRUG: Panobinostat|DRUG: QBM076|DRUG: HDM201
Sponsor: Novartis Pharmaceuticals